Homecare delivery and nursing support services

Pfizer provides you and your patients with a wide range of ongoing patient and clinical support at every stage of treatment with Genotropin (somatropin, rbe). 

The services offered are in line with the NICE Medicine’s Adherence Guideline 20091 and include:

  • Convenient, patient-centred product delivery and support for patients
  • Adherence monitoring facility, allowing for intervention where necessary to optimise outcomes and minimise waste.
  • Prescription management to ensure continuity of product supply and save nurses’ time.

Homecare delivery of Genotropin (somatropin, rbe)

Our service delivers your patients’ Genotropin where they want, when they want it.

Pfizer offers a free and flexible home delivery service of Genotropin to patients, ensuring patients have continuity of access to their treatment. This service is focused on adherence and making your patients life with growth hormone therapy as easy as possible.

Please contact the Pfizer freephone helpline on 0800 521249 for more information on this service.

Nursing support 

When starting Genotropin (somatropin, rbe) treatment in a new patient, Pfizer’s Home Nurse Service provides in-home device training by trained nurses.

Standard Services

  • Injection technique training (unlimited)
  • Telephone calls to conduct stock checks (unlimited)

Please contact the Pfizer freephone helpline on 0800 521249 for more information on this service.

Enhanced Services

  • Telephone calls to transition patients
  • Collection of patient experience data
  • Nurse clinic attendance at the hospital (1/2 day)
  • Bespoke service plans (e.g. blood tests, disease activity monitoring)

Enhanced services should be agreed locally with Pfizer. For more information please contact the Genotropin (somatropin) Nursing Support team by email at [email protected]

References

  1. NICE Guidance (2009) Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence.

https://www.nice.org.uk/guidance/cg76 (Last accessed March 2018)

 

PP-GEN-GBR-0468. July 2018